EFNB2 and neoplasm: This molecule, termed bi-directional ephrin agonist peptide (BIDEN-AP), can inhibit ephrin-B2 endothelial cell angiogenic signaling, while also activating EphB4 dependent tumor-suppressive signaling in tumor cells (Xiong et al., 2020).